Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

Weight loss leader Novo Nordisk has had a poor performance at ... trial results for its obesity and diabetes treatment CagriSema. The first big price fall came after the company released its ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

its next-generation weight loss drug CagriSema; and a move to diversify into rare diseases, with several data readouts expected this year. In 2025, Novo Nordisk is guiding for annual sales growth ...